AR071840A1 - Conjugados antitumorales de doble objetivo - Google Patents

Conjugados antitumorales de doble objetivo

Info

Publication number
AR071840A1
AR071840A1 ARP090101790A ARP090101790A AR071840A1 AR 071840 A1 AR071840 A1 AR 071840A1 AR P090101790 A ARP090101790 A AR P090101790A AR P090101790 A ARP090101790 A AR P090101790A AR 071840 A1 AR071840 A1 AR 071840A1
Authority
AR
Argentina
Prior art keywords
absent
formula
same
equal
different
Prior art date
Application number
ARP090101790A
Other languages
English (en)
Spanish (es)
Inventor
Claudio Pisano
Massimo Castorina
Sergio Penco
Loredana Vesci
Pozzo Alma Dal
Emiliano Esposito
Minghong Ni
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR071840A1 publication Critical patent/AR071840A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP090101790A 2008-05-20 2009-05-19 Conjugados antitumorales de doble objetivo AR071840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156575 2008-05-20

Publications (1)

Publication Number Publication Date
AR071840A1 true AR071840A1 (es) 2010-07-21

Family

ID=39765065

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101790A AR071840A1 (es) 2008-05-20 2009-05-19 Conjugados antitumorales de doble objetivo

Country Status (16)

Country Link
US (1) US20110160147A1 (https=)
EP (1) EP2285396A1 (https=)
JP (1) JP2011523415A (https=)
KR (1) KR20110022594A (https=)
CN (1) CN102036676A (https=)
AR (1) AR071840A1 (https=)
AU (1) AU2009249795A1 (https=)
BR (1) BRPI0911978A2 (https=)
CA (1) CA2724562A1 (https=)
EA (1) EA201071326A1 (https=)
IL (1) IL208920A0 (https=)
MX (1) MX2010012320A (https=)
NZ (1) NZ588948A (https=)
TW (1) TW201004647A (https=)
WO (1) WO2009141240A1 (https=)
ZA (1) ZA201009036B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
CA2770980A1 (en) 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CA2841249C (en) 2011-07-29 2023-09-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
EA031930B1 (ru) 2013-01-30 2019-03-29 Авелас Байосайенсиз, Инк. Молекула селективной доставки для визуализации злокачественной ткани
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10125124B2 (en) 2015-03-20 2018-11-13 Massachusetts Institute Of Technology Formation of macromolecules using iterative growth and related compounds
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
EA202191244A1 (ru) * 2018-11-05 2021-10-11 Байер Фарма Акциенгезельшафт Новые цитостатические конъюгаты с лигандами интегрина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370245A1 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
US8404650B2 (en) * 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof

Also Published As

Publication number Publication date
TW201004647A (en) 2010-02-01
CN102036676A (zh) 2011-04-27
EA201071326A1 (ru) 2011-06-30
JP2011523415A (ja) 2011-08-11
MX2010012320A (es) 2010-12-01
NZ588948A (en) 2011-10-28
ZA201009036B (en) 2012-01-25
IL208920A0 (en) 2011-01-31
AU2009249795A1 (en) 2009-11-26
WO2009141240A1 (en) 2009-11-26
KR20110022594A (ko) 2011-03-07
US20110160147A1 (en) 2011-06-30
EP2285396A1 (en) 2011-02-23
BRPI0911978A2 (pt) 2019-09-24
CA2724562A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
AR071840A1 (es) Conjugados antitumorales de doble objetivo
ES2739613T3 (es) Péptidos que penetran en las células y sus métodos de preparación y su uso
EP2476693A3 (en) Peptide vaccines for cancers expressing tumor-associated antigens
ES2258819T3 (es) Derivados de dolastina 15.
PH12013501656A1 (en) Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AR072610A1 (es) Composiciones para el tratamiento del dolor y/o la inflamacion
MX390359B (es) Formulaciones que contienen linaclotida para administracion oral
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
AR077956A1 (es) Combinaciones de compuestos activos
JP2011523415A5 (https=)
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
PE20091067A1 (es) Variantes de peptidos natriureticos de tipo c
AR055202A1 (es) Derivados de imidazolcarboxamida como inhibidores de fructosa -1,6- biofosfatasa y composiciones farmaceuticas que los contienen
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
JP2010536714A5 (https=)
Shetty et al. SUMO proteins in the cardiovascular system: friend or foe?
AR030278A1 (es) Peptido modulador del receptor de trombopoyetina
RU2012121562A (ru) Комбинация для лечения мукозита, индуцированного облучением или химиотерапией
ATE249842T1 (de) Zielgerichte arzneimittel abgabe für zulphonamide-derivate
ES2570458T3 (es) Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7
Lee et al. A cytotoxic fellutamide analogue from the sponge-derived fungus Aspergillus versicolor
GT200100145A (es) Derivados de pirrolidina.
DK2053929T3 (da) Resin-indkapslet højintensivt sødemiddel
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой

Legal Events

Date Code Title Description
FB Suspension of granting procedure